Carisma Therapeutics, Inc. (CARM)
CARM Stock Price Chart
Explore Carisma Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CARM price movements and trends.
CARM Company Profile
Discover essential business fundamentals and corporate details for Carisma Therapeutics, Inc. (CARM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Feb 2014
Employees
46.00
Website
https://carismatx.comCEO
Steven Kelly
Description
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
CARM Financial Timeline
Browse a chronological timeline of Carisma Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Mar 2026
Upcoming earnings on 5 Nov 2025
Earnings released on 7 Aug 2025
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 13 May 2025
EPS came in at -$0.22 falling short of the estimated -$0.12 by -83.33%, while revenue for the quarter reached $3.73M , beating expectations by +98.88%.
Earnings released on 31 Mar 2025
EPS came in at -$0.42 falling short of the estimated -$0.16 by -162.50%, while revenue for the quarter reached $3.65M , beating expectations by +48.03%.
Earnings released on 7 Nov 2024
EPS came in at -$0.31 matching the estimated -$0.31, while revenue for the quarter reached $3.39M , missing expectations by -37.56%.
Earnings released on 8 Aug 2024
EPS came in at -$0.27 surpassing the estimated -$0.36 by +25.00%, while revenue for the quarter reached $9.20M , beating expectations by +134.62%.
Earnings released on 9 May 2024
EPS came in at -$0.46 falling short of the estimated -$0.37 by -24.32%, while revenue for the quarter reached $3.40M , missing expectations by -22.80%.
Earnings released on 26 Mar 2024
EPS came in at -$0.52 surpassing the estimated -$0.55 by +5.45%, while revenue for the quarter reached $4.29M , beating expectations by +47.90%.
Earnings released on 9 Nov 2023
EPS came in at -$0.53 surpassing the estimated -$0.60 by +11.67%, while revenue for the quarter reached $3.83M , beating expectations by +31.51%.
Earnings released on 10 Aug 2023
EPS came in at -$0.49 surpassing the estimated -$0.66 by +25.76%, while revenue for the quarter reached $3.56M , beating expectations by +232.71%.
Earnings released on 11 May 2023
EPS came in at -$1.93 falling short of the estimated -$0.89 by -116.85%, while revenue for the quarter reached $3.24M , beating expectations by +1.34%.
Dividend declared on 8 Mar 2023
A dividend of $0.36 per share was announced, adjusted to $0.36.
Stock split effective on 8 Mar 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Feb 2023
EPS came in at -$0.80 surpassing the estimated -$2.20 by +63.64%, while revenue for the quarter reached $3.73M .
Earnings released on 7 Nov 2022
EPS came in at $2.00 surpassing the estimated -$3.10 by +164.52%, while revenue for the quarter reached $2.58M .
Earnings released on 8 Aug 2022
EPS came in at -$3.20 falling short of the estimated -$2.60 by -23.08%, while revenue for the quarter reached $2.70M .
Earnings released on 9 May 2022
EPS came in at -$0.32 surpassing the estimated -$2.00 by +83.82%, while revenue for the quarter reached $822.00K .
Earnings released on 28 Feb 2022
EPS came in at $0.80 surpassing the estimated -$1.47 by +154.42%, while revenue for the quarter reached $20.00M , missing expectations by -56.79%.
Earnings released on 8 Nov 2021
EPS came in at $7.20 surpassing the estimated -$1.40 by +614.29%.
Earnings released on 9 Aug 2021
EPS came in at -$3.00 falling short of the estimated -$1.27 by -136.22%, while revenue for the quarter reached $2.23M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$7.00 falling short of the estimated -$1.53 by -357.52%, while revenue for the quarter reached $4.31M , missing expectations by -53.22%.
Earnings released on 15 Mar 2021
EPS came in at -$2.20 falling short of the estimated -$2.13 by -3.29%, while revenue for the quarter reached $0.01 .
Earnings released on 9 Nov 2020
EPS came in at -$3.80 falling short of the estimated -$1.60 by -137.50%, while revenue for the quarter reached $11.24M .
CARM Stock Performance
Access detailed CARM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.